Can grooming momentum sustain? Watch for margin hold on pricing vs raw-material tailwinds
Gillette India enters Q2 FY27 (ending Sep 30) riding a 11% revenue and 9% profit lift from Q1. The Street expects 15–20% FY-wide PAT growth; for this quarter, the focus is whether the company can extend pricing gains, hold advertising spend, and keep grooming (82% of revenue) growing double-digit as the personal care cycle matures.
What to expect
~₹800–820 Cr
On track for double-digit growth (Q1: +11% YoY to ₹783 Cr); assume 8–10% sequential from grooming +pricing offsets volume maturity in oral care
~₹162–170 Cr
Expect 9–12% YoY growth (Q1: +9% to ₹159 Cr); margin hold hinges on pricing stickiness vs inflationary input cost swings
~₹665–685 Cr
Core 82% of topline; double-digit growth expected if volume + pricing both hold — FY27 guide assumes mid-teen% margin accretion
~₹145–155 Cr
Complementary 18% of topline; expect mid-single-digit growth — lower pricing power, but category gaining household penetration
A strong Q2 would show grooming revenue topping ₹680 Cr with margins intact or expanding — proof that pricing sticks even as market matures and input costs remain stable. Oral care growing 10%+ would signal broader portfolio strength. A weak Q2 would reveal volume pressure in grooming (deflation trade-downs or reduced purchase frequency), compressed margins, or surprising advertising cost inflation — red flags for the FY27 15–20% PAT growth narrative.
On track?
Gillette India is tracking the Street's 15–20% FY27 PAT growth expectation based on Q1's 9% profit lift. The company has signaled mid-teen% margin accretion for the year, implying that grooming's pricing power will offset any volume deceleration and that the oral care ramp can run without eroding the overall mix. Q2 is the first true test: if profit growth dips below 8%, the full-year guide becomes at-risk. The stock is down 34% from ATH (₹11,266) to ₹7,407 — valuation is cheap on consensus, but execution must hold.
What the Street says
Since last quarter
1 · Management reshuffle — new Executive Director appointed
Robin Thadathil joined as Additional (Executive) Director on Aug 1, 2026, bringing 16+ years of FMCG experience. This signals management continuity and operational focus — no governance risk.
2 · LIC stake sale flagged — 2.01% reduced holdings
Life Insurance Corporation of India sold 655,952 shares in late August — a modest portfolio rebalance. Promoter holding remains rock-solid at 75%; no material risk to control.
3 · AGM held, 42nd Annual Report released
August 31, 2026 shareholder meeting approved director appointments and reaffirmed Board slate. Business Responsibility and Sustainability Report (BRSR) filed — routine corporate governance.
4 · Trading window closure — Sep 28 to Nov 13
Board announced closure of trading window for designated persons effective Oct 1 through 48 hours post-result. Standard pre-result protocol; no signal embedded.
The setup
Gillette India enters Q2 FY27 (ended Sep 30) with tailwinds from Q1's 11% revenue and 9% profit growth, a new Executive Director, and a Street consensus of 15–20% FY-wide PAT growth anchored on margin accretion and pricing power in grooming. At ₹7,407 (down 34% from ATH), valuation is attractive if execution holds.
Three things to watch on Nov 13: (1) Grooming revenue — does it sustain 8–10% sequential growth or show deceleration under volume pressure? (2) Margins — does net profit growth hold above 9% or reveal input-cost headwinds despite pricing? (3) FY27 guide — any reset to the 15–20% PAT growth consensus, or confidence reaffirmed? If Q2 shows margin compression and grooming volume stalling, the Street will reprice risk down. If both hold, the path to ₹10k+ is credible.